A Phase I Dose-Escalation Study of Erlotinib in Combination with Cetuximab in Subjects with Advanced Cancer. Companion study to umbrella protocol 2007-0638.
Phase of Trial: Phase I
Latest Information Update: 10 Jul 2015
At a glance
- Drugs Cetuximab (Primary) ; Erlotinib (Primary)
- Indications Cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 10 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Jul 2013 Planned end date changed from 1 Apr 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov.